文献速递冠心病血脂与心血管预防

急性冠脉综合征后动脉粥样硬化血栓形成的长期预防药物治疗

Medical Therapy for Long-Term Prevention of Atherothrombosis Following an Acute Coronary Syndrome: JACC State-of-the-Art Review.
PubMed 文献 · J Am Coll Cardiol · 2018-01-01

该综述指出急性冠脉综合征(ACS)后动脉粥样硬化血栓事件风险可持续多年,病理生理学进展从单一「易损斑块」转向「易损患者」整体观,凸显药物治疗在二级预防中的核心地位。尽管遵循指南导向药物治疗,部分患者仍因残余风险发生复发性动脉粥样硬化血栓形成,近期临床试验强调血小板、凝血、胆固醇和全身炎症的关键作用,并支持个体化靶向治疗策略。

要点

  • ACS后动脉粥样硬化血栓风险持续多年,需长期二级预防。
  • 病理生理学从「易损斑块」转向「易损患者」整体观,强调药物治疗核心地位。
  • 指南导向治疗后仍有残余风险,涉及血小板、凝血、胆固醇和炎症,支持个体化靶向治疗。

核心结论

  • ACS后动脉粥样硬化血栓形成风险可持续多年,药物治疗是长期二级预防的基石。
  • 尽管遵循指南导向药物治疗,部分患者仍因残余风险发生复发性动脉粥样硬化血栓形成。
  • 近期临床试验强调血小板、凝血、胆固醇和全身炎症在残余风险中的关键作用,支持个体化靶向治疗。

研究设计与样本

  • 本文为JACC state-of-the-art综述,总结ACS后动脉粥样硬化血栓形成二级预防的进展证据。

主要发现

  • ACS后对动脉粥样硬化血栓事件的易感性可持续多年。
  • 对ACS病理生理学的认识从单一「易损斑块」转向「易损患者」整体观。
  • 指南导向药物治疗后,部分ACS后患者仍发生复发性动脉粥样硬化血栓形成。
  • 近期临床试验强调血小板、凝血、胆固醇和全身炎症在残余风险中的作用。
  • 新兴数据揭示此前未认识的残余风险因素。

临床怎么用

  • ACS后应坚持长期二级预防药物治疗,并关注指南导向治疗后的残余风险。
  • 残余风险管控需综合考虑血小板、凝血、胆固醇和全身炎症等靶点。
  • 基于残余风险因素探索个体化、靶向的二级预防策略。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Following an acute coronary syndrome (ACS), heightened predisposition to atherothrombotic events may persist for years. Advances in understanding the pathobiology that underlies this elevated risk furnish a mechanistic basis for devising long-term secondary prevention strategies. Recent progress in ACS pathophysiology has challenged the focus on single "vulnerable plaques" and shifted toward a more holistic consideration of the "vulnerable patient," thus highlighting the primacy of medical therapy in secondary prevention. Despite current guideline-directed medical therapy, a consistent proportion of post-ACS patients experience recurrent atherothrombosis due to unaddressed "residual risk": contemporary clinical trials underline the pivotal role of platelets, coagulation, cholesterol, and systemic inflammation and provide a perspective on a personalized, targeted approach. Emerging data sheds new light on heretofore unrecognized residual risk factors. This review aims to summarize evolving evidence relative to secondary prevention of atherothrombosis, with a focus on recent advances that promise to transform the management of the post-ACS patient.

来源:J Am Coll Cardiol,查看原文。版权归原作者所有。

引用

  1. Gallone G, Baldetti L, Pagnesi M, et al. Medical Therapy for Long-Term Prevention of Atherothrombosis Following an Acute Coronary Syndrome: JACC State-of-the-Art Review. J Am Coll Cardiol. 2018. PMID: 30522652. doi:10.1016/j.jacc.2018.09.052

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。